Drug-Resistant Melanoma Tumors Shrink When Therapy Is Interrupted, University of California, San Francisco (UCSF), Novartis Institutes for BioMedical Research, and University Hospital Zurich Study

Researchers in California and Switzerland have discovered that melanomas that develop resistance to the anti-cancer drug vemurafenib (marketed as Zelboraf), also develop addiction to the drug, an observation that may have important implications for the lives of patients with late-stage disease.